-

Warner Bros. Discovery, Inc. Equity Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Warner Bros. Discovery, Inc. (WBD)

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities who (1) exchanged Discovery, Inc. common stock for Warner Bros. Discovery, Inc. (NASDAQ: WBD) common stock pursuant or traceable to Discovery’s February 4, 2022 Registration Statement on Form S-4 (the “Registration Statement”) and Joint Proxy Statement/Prospectus filed with the SEC on February 10, 2022 (the “Prospectus”), or (2) purchased shares of WBD common stock on the open market traceable to the Prospectus through the date of the filing of this Complaint. The complaint is also brought on behalf of Discovery shareholders who exchanged Discovery common shares for WBD common stock pursuant to the Prospectus.

If you would like more information about Warner Bros. Discovery, Inc.'s misconduct, click here.

What is this Case About: Defendants Made False and Misleading Statements in Connection with the Merger Between Discovery, Inc. and the WarnerMedia division of AT&T, Inc.

According to the complaint, Discovery and the WarnerMedia division of AT&T, Inc. completed its merger on April 8, 2022. After the merger, Discovery's former senior officers – named as individual defendants in the class action – managed WBD. At the time of filing the Registration Statement and Prospectus, Discovery and the individual defendants knew or had access to adverse information concerning operations of the WarnerMedia business. However, defendants failed to disclose this information to Discovery shareholders prior to the vote on the merger.

Specifically, defendants failed to disclose that: (i) WarnerMedia’s HBO Max streaming business had a high churn rate that made the business not “viable” unless the churn rate was reversed; (ii) AT&T was overinvesting in WarnerMedia entertainment content for streaming, without sufficient concern for return on investments; (iii) WarnerMedia had a business model to grow the number of subscribers to its streaming service without regard to cost or profitability; (iv) WarnerMedia was improvidently concentrating its investments in streaming and ignoring its other business lines; and (v) WarnerMedia had overstated the number of subscribers to HBO Max by as many as 10 million subscribers, by including as subscribers AT&T customers who had received bundled access to HBO Max, but had not signed onto the service.

Between April 11, 2022, the first trading day after completion of the merger, and September 22, 2022, WBD's stock price fell by 52.4%, from $24.78 to $11.79 per share, as the market became aware of the foregoing misrepresented and omitted facts.

Next Steps: If you acquired shares of Warner Bros. Discovery, Inc. pursuant to the merger between Discovery and the WarnerMedia division of AT&T, you have until November 22, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Warner Bros. Discovery, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:WBD

Release Summary
Defendants Made False and Misleading Statements in Connection with the Merger Between Discovery, Inc. and the WarnerMedia division of AT&T, Inc.
Release Versions

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Franklin BSP Realty Trust, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Franklin BSP Realty Trust, Inc. (NYSE: FBRT) securities between November 5, 2024 and February 11, 2026. FBRT is a real estate investment trust that "originates, acquires and manages a diversified portfolio of commercial real estate debt secured by properties located in the United States." For more information, submit a form, email attorney Aar...

Investor Notice: Robbins LLP Informs Investors of the Snowflake Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Snowflake Inc. (NYSE: SNOW) Class A common stock between June 27, 2023 and February 28, 2024. Snowflake is a software company that provides cloud data storage that enables customers to consolidate data onto data-driven applications and share data for the purpose of running analytics and other processes. For more information, submit a form, ema...

Investor Notice: Robbins LLP Informs Investors of the Class Action Lawsuit on Behalf of Zynex, Inc. Stockholders

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYKIQ) securities between February 25, 2021 and December 15, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis, and cardiac monitoring. For more information, submit a form, email attorney Aaron Dumas, Jr....
Back to Newsroom